Eledon Pharmaceuticals, Inc. (ELDN) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Irvine, CA, 미국. 현재 CEO는 David-Alexandre C. Gros.
ELDN 을(를) 보유 IPO 날짜 2014-09-17, 31 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $191.84M.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
